Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, no more than one previous chemotherapy regimen, no prior treatment with PARP inhibitor

Type of study:

Phase I study

Treatment:

Participants will be in one of two groups:

28-day cycles with veliparib orally on days 1-7 and doxorubicin hydrochloride intravenously and carboplatin intravenously on day 1. (Some patients may also receive bevacizumab intravenously on day 1 and 15.)

28-day cycles with veliparib orally daily and doxorubicin hydrochloride intravenously and carboplatin intravenously on day 1. (Some patients may also receive bevacizumab intravenously on day 1 and 15.)

Receive the latest updates from FORCE

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.